Meet The Researcher

I cycle between 300 and 500 km per week.

I wanted to understand why some people develop MS with a view to finding potential treatments for what was then an untreatable condition. I did not want to see any more young lives ruined.

The development of multiple very effective therapies for the early inflammatory stage of MS.

The RAMBLE Trial hopes to reduce the frequency of autoimmune adverse events seen with one of the most effective therapies for MS, alemtuzumab.

Autoimmune disease is the single major drawback of alemtuzumab treatment for MS. When used early on this treatment is close to being curative for the vast majority and removing this adverse aspect of this treatment would make this a more appealing option for more people with MS.

I enjoy collaborating with my colleagues around Australia and around the world, but mostly I enjoy what I hope is a small positive impact on the journey of the people with MS that I treat.